| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10428 | (1S,3R,5R)-PIM447 dihydrochloride | (1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3. |
-PIM447 dihydrochloride.gif)
|
| DC12010 | ML116 | A novel selective STAT3 inhibitor with IC50 of 4.2 uM, does not inhibit STAT1, STAT5, or NFkB signaling pathways (IC50>50 uM). |
|
| DC11882 | HJC0416 | A orally bioavailable small-molecule STAT3 inhibitor. |
|
| DC12009 | CPA-7 | A platinum-containing compound that disrupts STAT3 signaling, inhibits cell growth and induces apoptosis in STAT3-activated cancer cells. |
|
| DC21158 | JAK3-IN-2 Featured | A potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM. |
|
| DC11736 | PF-956980 | A potent, highly specific JAK3 inhibitor with IC50 of 4 nM. |
|
| DC2096 | AG490 Featured | AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
|
| DC8256 | AS 602801(Bentamapimod) Featured | AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK. |
|
| DC11420 | AS-1517499 Featured | AS1517499 is a potent STAT6 inhibitor with IC50 of 21 nM. |
|
| DC7367 | AZ-960 Featured | AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. |
|
| DC5012 | AZD-1208 Featured | AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. |
|
| DC5032 | AZD1480 Featured | AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2. |
|
| DC5064 | Baricitinib (INCB28050, LY3009104) Featured | Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC8258 | Baricitinib phosphate Featured | Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2). |
|
| DC4175 | BMS-911543 Featured | BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. |
|
| DC8040 | STAT3 Inhibitor XVIII, BP-1-102 Featured | BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor. |
|
| DC9704 | Unii-G55ZH52P57 Featured | BTZ043 is a inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), It can display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro. |
|
| DCAPI1392 | BTZ043 racemate Featured | BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2-epimerase (DprE1) inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis. |
|
| DC10864 | C188-9 Featured | C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors. |
|
| DC7099 | CEP33779 Featured | CEP33779(< 3 μM) inhibits phosphorylation of downstream target signal transducer and activator of transcription 5(pSTAT5) of JAK2 in a concentration dependent manner in HEL92 cells. |
|
| DC7814 | Cerdulatinib(PRT-062070; PRT2070) Featured | Cerdulatinib(PRT-062070; PRT2070) is an novel oral dual Syk/JAK inhibitor. |
|
| DC10341 | CHZ868 | CHZ868 is a type II JAK2 inhibitor with an IC50 of 0.17 μM in EPOR JAK2 WT Ba/F3 cell. |
|
| DC7153 | CX6258 Featured | CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity. |
|
| DC3107 | Momelotinib (CYT387,CYT-387) Featured | CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively. |
|
| DC10111 | Debio 0617B | Debio 0617B has been developed as a first-in-class kinase inhibitor with a unique profile targeting phospho-STAT3 (pSTAT3) and/or pSTAT5 in tumors through combined inhibition of JAK, SRC, ABL, and class III/V receptor tyrosine kinases (RTK). |
|
| DC8171 | Decernotinib (VX-509,adelatinib) Featured | Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays. |
|
| DC11890 | Delgocitinib Featured | Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively. |
|
| DC8726 | FLLL31 Featured | FLLK31 is a potent and selective inhibitor of the STAT3 signaling pathway. |
|
| DC7751 | FLLL32 Featured | FLLL32, a novel curcumin analogue, is a potent STAT3 inhibitor. |
|
| DC10826 | FM-381 Featured | FM-381 is a JAK3 specific reversible covalent inhibitor with IC50 of 127 pM for JAK3 and demonstrates 400-, 2,700- and 3,600-fold selectivity over JAK1, JAK2, and TYK2, respectively. |
|
